ArticleInternational journal of hematology2025
Mechanism of antithrombin deficiency due to the novel variant C32W in the C-terminus of the signal peptide.
Article in International journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Signal Peptides: From Molecular Mechanisms to Applications in Protein and Vaccine Engineering.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionWe identified a novel variant of the antithrombin (AT) gene (SERPINC1), c.96 T>G, p.Cys32Trp (C32W), located at the signal peptide cleavage site in a patient with congenital AT deficiency. The impact of signal peptide variants on the intracellular trafficking and secretion of AT proteins has not been previously studied. Thus, we analyzed the intracellular dynamics and signal peptide cleavage of the C32W variant of AT (AT-C32W). MATERIALS AND
methodsWild-type AT (AT-WT) and AT-C32W expression vectors were transfected into HEK293 cells. Functional analyses were performed using western blotting and proteasome inhibition experiments. Signal peptide cleavage was evaluated by peptide sequencing.
resultsThe AT antigen levels in the cell lysates and culture supernatants of the AT-C32W were reduced to 3.8% and 4.8%, respectively. Following proteasome inhibition, the AT-C32W level increased to 71.5% of that for AT-WT. Peptide sequencing identified a fragment corresponding to the N-terminal end of the signal peptide exclusively in AT-C32W. DISCUSSION: These results suggest that the signal peptide of AT-C32W is not cleaved properly, which causes intracellular degradation of AT-C32W by proteasomes that results in type I AT deficiency. Further studies on the intracellular dynamics of such variants may clarify the mechanisms underlying AT deficiency.
Indexed as
Identifiers
39928217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.